Synonyms 2-Methoxyestra-1,3,5(10)-triene-3,17β-diol
CAS Number 362-07-2 N
PubChem (CID) 66414
ChemSpider 59788 YesY
ChEBI CHEBI:28955 YesY
Chemical and physical data
Formula C19H26O3
Molar mass 302.408 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

2-Methoxyestradiol (2-ME2) is a natural metabolite of estradiol. As an experimental drug candidate, it is being developed under the tradename of Panzem.[1] It prevents the formation of new blood vessels that tumors need in order to grow (angiogenesis), hence it is an angiogenesis inhibitor.[2]

It also acts as a vasodilator.

2-ME2 is derived from estradiol, although it binds poorly (2000-fold lower activational potency) to known estrogen receptors.[3] However, 2-ME2 retains activity as a high-affinity agonist of the GPER (GPR30).[4]

It induces apoptosis in some cancer cell lines.[5]

It has undergone Phase 1 clinical trials against breast cancer.

A phase II trial of 18 advanced ovarian cancer patients reported encouraging results in Oct 2007.[6]

Preclinical models also suggest that 2-ME2 could also be effective against inflammatory diseases such as rheumatoid arthritis. Several studies have been conducted showing 2-ME2 is a microtubule-inhibitor[7] and effective against prostate cancer in rodents.

As of 2015, all clinical development of 2-ME2 has been suspended or discontinued.[8]

See also


  1. EntreMed's Product Information Site Archived May 4, 2005, at the Wayback Machine.
  2. 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Pribluda VS, et al. Cancer Metastasis Rev. 2000;19(1-2):173-9. Review.
  3. Dose-response effects of 2-methoxyestradiol on estrogen target tissues in the ovariectomized rat. Sibonga JD et al. Endocrinology. 2003 Mar;144(3):785-92. PMID 12586754
  4. Thekkumkara, Thomas; Snyder, Russell; Karamyan, Vardan T. (2016). "Competitive Binding Assay for the G-Protein-Coupled Receptor 30 (GPR30) or G-Protein-Coupled Estrogen Receptor (GPER)". 1366: 11–17. doi:10.1007/978-1-4939-3127-9_2. ISSN 1064-3745.
  5. LaValee; et al. (2003). "2-Methoxyestradiol Up-Regulates Death Receptor 5 and Induces Apoptosis through Activation of the Extrinsic Pathway". 63 (2): 468–75. PMID 12543804.
  6. "EntreMed Presents Results for Panzem® NCD Phase 2 Ovarian Cancer Study". Archived from the original on July 17, 2012.
  7. Lakhani, NJ; Sarkar, MA; Venitz, J; Figg, WD (2003). "2-Methoxyestradiol, a promising anticancer agent". Pharmacotherapy. 23 (2): 165–72. doi:10.1592/phco. PMID 12587805.
  8. http://adisinsight.springer.com/drugs/800008361

External links

This article is issued from Wikipedia - version of the 11/14/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.